FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.277 USD
0.0127 (4.59%)
Valuation Date:
Mar 17, 2025 4:00 PM
Share Price on Valuation Date
$0.28
Stock Beta
0.436
Shares Outstanding
7241440